Lv1
13 积分 2021-01-25 加入
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
7天前
已完结
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
15天前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
15天前
已完结
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
15天前
已完结
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer
15天前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
16天前
已完结
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer
19天前
已完结
Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer
1个月前
已完结
Population Health Colorectal Cancer Screening Strategies in Adults Aged 45 to 49 Years
1个月前
已完结
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
1个月前
已完结
皖公网安备34019202002308
